By Professor David Thomas

Book Chapters

Lin FP; Tran M; Thavaneswaran S; Grady JP; Kansara M; Chan J; Ballinger ML; Simes J; Thomas DM, 2025, 'Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models', in , pp. 248 - 252, http://dx.doi.org/10.3233/SHTI250839

Neuhaus SJ; Thomas DM, 2017, 'Multidisciplinary approach to treatment: An Australian perspective', in Sarcoma: A Multidisciplinary Approach to Treatment, Springer, pp. 461 - 476, http://dx.doi.org/10.1007/978-3-319-43121-5_23

Thomas DM; Whelan J, 2017, 'Bone Sarcomas in the Adolescent and Young Adult Population', in Bleyer A; Barr R; Ries L; Whelan J; Ferrari A (ed.), Cancer in Adolescents and Young Adults., Springer, pp. 417 - 427, http://dx.doi.org/10.1007/978-3-319-33679-4_16

Orme LM; Palmer S; Thomas D, 2009, 'No-man’s land: Between paediatric and adult medical oncology', in When Cancer Crosses Disciplines A Physician S Handbook, pp. 885 - 906, http://dx.doi.org/10.1142/9781848163652_0035

Journal articles

Liang S; Kennedy E; Gale N; Watson P; Ramanathan M; Shinde A; McKay S; Torres-Robles A; Li Z; Chan J; Jones H; Ballinger ML; Butow P; Goldstein D; Leaney K; Middleton S; Morrow A; Thomas DM; Tucker KM; Zaheed M; Parkinson B; Lin F; Taylor N, 2025, 'Implementation of precision medicine in treating non-communicable diseases: a systematic review', Journal of Translational Medicine, 23, http://dx.doi.org/10.1186/s12967-025-07201-y

Gheybi K; Soh PXY; Jiang J; Mbeki TMN; Louw M; Burns D; Mundra P; Kiriy D; Hasan MM; Jaratlerdsiri W; Lebelo MT; Campbell RA; Radzuma MB; Nenzhelele M; Obida M; Obida M; Ombuki WM; Oyaro MO; Patrick SM; Loda M; Wedge DC; Bristow RG; Brewer DS; Cooper CS; Reimand J; Cancel-Tassin G; Cussenot O; Hovens CM; Cocoran NM; Stricker PD; Schlomm T; Prins GS; Sørensen KD; Zanettini C; Yamaguchi TN; Xu Y; Uhrig S; Soh PXY; Sahli A; Robinson B; Reimand J; Rausch T; Queiroz LR; Pope B; Pellegrina D; Papenfuss AT; Molania R; Marchionni L; Lutsik P; Leeman G; Lamy P; Khani F; Jung CH; Jiang J; Jaratlersiri W; Jakobsdottir GM; Imada EL; He HH; Hayes VM; Hamid A; Gruber AJ; Gnanapragasam VJ; Girma EG; Gihawi A; Gerhauser C; Favero F; Corcoran NM; Cheng KCL; Butler A; Brors B; Brook MN; Bova GSS; Zhou K; Yienya A; Wanjiku GS; Walong EOO; Walker DI; Uthayopas K; Tapinos A; Stellmacher G; Shirinde J; Oyieko W; Nyaga ME; Menoe R; Maendo U; Kote-Jarai Z; Huang R; Holmes V; Gong T; Gamxamub J; Förtsch HEA; Jensby EF; Fanelli GN; Craddock J; Birch L; Barnhoorn IEJ; Argos M; Madueke IC; Moreira DM, 2025, 'Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-63865-6

van der Graaf WTA; Heiss NS; Hynes CL; Keller SP; Weinman A; Blay JY; Franco P; Giles RH; Lacombe D; Schlatter P; Thomas DM; van Waalwijk van Doorn-Khosrovani SB; Williamson M; Plummer R, 2025, 'Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action', Cancer Treatment Reviews, 140, http://dx.doi.org/10.1016/j.ctrv.2025.103013

Serrano C; Bauer S; Blay J-Y; Casali PG; Cicala CM; Dei Tos AP; Digklia A; Gelderblom H; Italiano A; Jones RL; Kasper B; Kyriazoglou A; Le Loarer F; Martín-Broto J; Napolitano A; Rutkowski P; Stacchiotti S; Tap W; Thomas D; Thway K; Valverde C; van der Graaf WTA; Wardelmann E; Bovée JVMG, 2025, 'Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.', JAMA Oncol, http://dx.doi.org/10.1001/jamaoncol.2025.3608

Liang S; McKay S; Lin F; Zaheed M; Morrow A; Douglas B; Chan J; Monaghan H; Chan P; Kennedy E; Tyedmers E; Walker S; Leaney K; Napier CE; Middleton S; Butow P; Williams R; Parkinson B; Ballinger ML; Tucker K; Goldstein D; Thomas D; Taylor N, 2025, 'Integration of precision medicine into routine cancer care—protocol for the Precision Care Initiative: a research programme of effectiveness-implementation hybrid trials', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-090270

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; Mackenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; Defazio A; Filipits M; Flynn PJ; Dinny Graham J; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Gao B; Carlino MS; Michael M; Underhill C; Marshall H; Gunjur A; So J; Kee D; Antill Y; Lam WS; Chan H; Harrup R; Hamilton A; Grady J; Ballinger M; Tavancheh E; Yoon WH; Palmer J; Thomas D; Wilkie K; Cebon J; Klein O, 2025, 'Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 11, pp. 982 - 989, http://dx.doi.org/10.1001/jamaoncol.2025.1916

Thavaneswaran S; Sim HW; Grady J; Espinoza D; Huang ML; Lin F; McGrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339

Zhu Y; Lin FP-Y; So JY; Oh EW; Philipsen S; Thomas DM; Grady JP; Lawrence BJ; Wilson MK, 2025, 'Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) program in New Zealand (NZ) depending on residence in NZ or Australia.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. E13763 - E13763, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13763

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning-based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13683

Connolly EA; Boye K; Bonvalot S; Kratz CP; Leithner A; Malkin D; Messiou C; Miah AB; Pantziarka P; Timmermann B; van der Graaf WTA; Thomas DM; Stacchiotti S, 2025, 'Genetic predisposition in sarcomas: clinical implications and management', Eclinicalmedicine, 83, http://dx.doi.org/10.1016/j.eclinm.2025.103203

Gadgeel SM; Fajardo O; Barlesi F; Eun Kim J; Kurzrock R; Thomas DM; Jagtiani R; Noe J; Schwemmers S; Nikolaidis C, 2025, 'Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf005

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, pp. e087922, http://dx.doi.org/10.1136/bmjopen-2024-087922

Jung MS; Poltavets V; Skhinas JN; Tax G; Kamili A; Xie J; Ghamrawi S; Graber P; Mao J; Wong-Erasmus M; Cui L; Kimpton K; Venkat P; Mayoh C; Lin A; Fleuren EDG; Fordham AM; Barger Z; Grady J; Thomas DM; Du EY; Graf NS; Cowley MJ; Gifford AJ; Fletcher JI; Lau LMS; Dolman MEM; Gooding JJ; Kavallaris M, 2025, 'High-throughput 3D engineered paediatric tumour models for precision medicine', Molecular Systems Biology, http://dx.doi.org/10.1038/s44320-025-00152-y

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058

Ballinger ML; Thomas DM, 2025, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, 33, pp. 3 - 4, http://dx.doi.org/10.1038/s41431-024-01676-x

Horgan D; Tanner M; Aggarwal C; Thomas D; Grover S; Basel-Salmon L; Dienstmann R; Tan TJY; Park WY; Abu Rasheed HM; Siu LL; Ma B; Ortiz-López R; Van Den Bulcke M; Taucher SC; Ferris A; Starling N; Malapelle U; Longshore J; Saldaña HAB; Subbiah V, 2025, 'Precision Oncology: A Global Perspective on Implementation and Policy Development', JCO Global Oncology, 11, http://dx.doi.org/10.1200/GO-24-00416

Borland ML; Loveys K; Babl FE; Cotterell E; Haskell L; O'Brien S; Oakley E; Wilson CL; Alsweiler J; Armstrong D; Craig SS; Crawford NW; Crellin D; Crone S; Duke T; George S; Jeffries-Stokes C; Krishnan N; Lithgow A; Peacock K; Ratoni T; Richmond P; Smith A; Starkie R; Thomas D; Wallace A; Zhang M; Tavender E; Dalziel SR; Paediat REDICPREDICTN, 2025, 'Australasian Bronchiolitis Guideline: 2025 Update', JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 61, pp. 1197 - 1215, http://dx.doi.org/10.1111/jpc.70144

Spencer S; Ye W; Napier C; Lin FP-Y; Thomas DM; Chan R; Ballinger ML; Morton RL; Berber S; Zou D; Peng S, 2025, 'Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e15084

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120

Kohlmann W; Curtin K; Madsen MJ; Camp NJ; Jeter JM; Ballinger ML; Thomas DM; Garber JE; Schiffman JD, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria.', Journal of Clinical Oncology, 43, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11570

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay JY; Ray-Coquard I, 2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study', Metabolomics, 20, http://dx.doi.org/10.1007/s11306-024-02178-z

Takeda K; Nakayama M; Hayakawa Y; Kojima Y; Ikeda H; Imai N; Ogasawara K; Okumura K; Thomas DM; Smyth MJ, 2024, 'Correction to: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting (Nature Communications, (2017), 8, 1, (14607), 10.1038/ncomms14607)', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-53456-2

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

Gianferante DM; Moore A; Spector LG; Wheeler W; Yang T; Hubbard A; Gorlick R; Patiño-Garcia A; Lecanda F; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Thomas DM; Ballinger ML; Serra M; Hattinger C; Demerath E; Johnson W; Birmann BM; De Vivo I; Giles G; Teras LR; Arslan A; Vermeulen R; Sample J; Freedman ND; Huang WY; Chanock SJ; Savage SA; Berndt SI; Mirabello L, 2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432

Best MC; Butow P; Savard J; Newson AJ; Campbell R; Vatter S; Napier CE; Bartley N; Tucker K; Ballinger ML; Thomas DM; Juraskova I; Schlub T; Davies G; Meiser B; Goldstein D, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074

Dziadziuszko R; Barlesi F; Kim JE; Gadgeel SM; Krzakowski M; Jeong JH; Daniele G; Chen D; Hu Y; Wilson TR; Simmons BP; Thomas DM, 2024, 'Atezolizumab in patients (pts) with tumor mutational burden (TMB)-high tumors from the TAPISTRY trial.', JOURNAL OF CLINICAL ONCOLOGY, 42, pp. LBA2509 - LBA2509, http://dx.doi.org/10.1200/JCO.2024.42.17_suppl.LBA2509

Barjesteh van Waalwijk van Doorn-Khosrovani S; Kholmanskikh Van Criekingen O; Koole S; Thomas DM; Gelderblom H, 2024, 'Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development', Cancer Cell, 42, pp. 923 - 929, http://dx.doi.org/10.1016/j.ccell.2024.05.014

Thomas DM; Daniele G; Kim JE; Gadgeel SM; Ahn ER; Paz-Ares LG; Prenen H; Chen D; Fang J; Wilson TR; Simmons BP; Barlesi F, 2024, 'Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.', Journal of Clinical Oncology, 42, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3092

Mirabello L; Egolf LE; Zhu B; Gianferante DM; Wang K; Li SA; Machiela MJ; Spector LG; Schiffman JD; Sabo A; Renwick A; Martin-Giacalone B; Scheurer ME; Plon S; Hawkins D; Venkatramani R; Stewart D; Morton LM; Hudson MM; Armstrong GT; Bhatia S; Dean M; Janeway KA; Patino-Garcia A; Lecanda F; Serra M; Hattinger C; Scotlandi K; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Delattre O; Hubbard AK; Liu J; Luo W; Hicks BD; Yeager M; Rafati M; Huang W-Y; Landi MT; Lori A; Diver R; Savage SA; Chanock SJ; Lupo PJ, 2024, 'Underlying germline genetic architecture of pediatric sarcomas: Evaluating the role of common and rare variants in 4,160 patients', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.AM2024-775

Freeman B; Peters MJ; Bittoun R; Brightwell R; English DR; Thomas DP; Otlowski MFA; Zwar NA; Chamberlain C, 2024, 'National Health and Medical Research Council statement on electronic cigarettes: 2022 update', Medical Journal of Australia, 220, pp. 100 - 106, http://dx.doi.org/10.5694/mja2.52163

Ringborg U; von Braun J; Celis J; Baumann M; Berns A; Eggermont A; Heard E; Heitor M; Chandy M; Chen CJ; Costa A; De Lorenzo F; De Robertis EM; Dubee FC; Ernberg I; Gabriel M; Helland Å; Henrique R; Jönsson B; Kallioniemi O; Korbel J; Krause M; Lowy DR; Michielin O; Nagy P; Oberst S; Paglia V; Parker MI; Ryan K; Sawyers CL; Schüz J; Silkaitis K; Solary E; Thomas D; Turkson P; Weiderpass E; Yang H, 2024, 'Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023', Molecular Oncology, 18, pp. 245 - 279, http://dx.doi.org/10.1002/1878-0261.13575

Mersiades AJ; Solomon Benjamin J; Thomas David M; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OMH; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N, 2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366

Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; Investigators KCF; James PA; Spurdle AB, 2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453

Cho D; Lord SJ; Ward R; IJzerman M; Mitchell A; Thomas DM; Cheyne S; Martin A; Morton RL; Simes J; Lee CK, 2024, 'Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241273062

Sargen MR; Kim J; Haley JS; Barker HP; Mundra PA; Ballinger ML; Thomas DM; Carey DJ; Goldstein AM; Stewart DR, 2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895

Klein O; Carlino M; Brown M; Harris SJ; Gunjur A; Underhill CR; Zielinski R; Kee D; Lam W-S; Chan H; Harrup RA; So J; Collins I; Michael M; Torres J; Palmer JB; Thomas D; Wilkie K; Cebon J; Nagrial A, 2024, '282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer', Annals of Oncology, 35, pp. S119 - S119, http://dx.doi.org/10.1016/j.annonc.2024.05.288

Klein O; Gao B; Chan H; Michael M; Zielinski R; So J; Harris SJ; Kee D; Collins IM; Lam W-S; Lyle M; Underhill CR; Brown M; Harrup RA; Wong SF; Palmer JB; Thomas D; Wilkie K; Cebon J; Carlino MS, 2024, '998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study', Annals of Oncology, 35, pp. S679 - S680, http://dx.doi.org/10.1016/j.annonc.2024.08.1057

Walpole IR; Zaman FY; Zhao P; Marshall VM; Lin FP; Thomas DM; Shackleton M; Antolin AA; Ameratunga M, 2024, 'Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases', CLINICAL AND TRANSLATIONAL MEDICINE, 14, http://dx.doi.org/10.1002/ctm2.1657

Klein O; Carlino MS; Michael M; Underhill CR; So J; Kee D; Antill Y; Lam W-S; Chan H; Harrup RA; Hamilton A; Palmer JB; Thomas DM; Wilkie K; Cebon J; Gao B, 2024, 'Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial', ANNALS OF ONCOLOGY, 35, pp. S546 - S547, http://dx.doi.org/10.1016/j.annonc.2024.08.775

Sharaf R; Jin DX; Grady J; Napier C; Ebot E; Frampton GM; Albacker LA; Thomas DM; Montesion M, 2023, 'A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content', Npj Genomic Medicine, 8, http://dx.doi.org/10.1038/s41525-023-00369-6

Lu CY; Terry V; Thomas DM, 2023, 'Precision medicine: affording the successes of science', Npj Precision Oncology, 7, http://dx.doi.org/10.1038/s41698-022-00343-y

Vaghjiani VG; Cochrane CR; Jayasekara WSN; Chong WC; Szczepny A; Kumar B; Martelotto LG; McCaw A; Carey K; Kansara M; Thomas DM; Walkley C; Mudge S; Gough DJ; Downie PA; Peacock CD; Matsui W; Watkins DN; Cain JE, 2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A, 2023, 'Modified study designs to expand treatment options in personalised oncology: a multistakeholder view', European Journal of Cancer, 194, http://dx.doi.org/10.1016/j.ejca.2023.113278

Back to profile page